Company intelligence / Profile preview

InspirMed

Ownership: Private
Development stage: Other

Overview

InspirMed develops inhalable liposome formulations of existing antiviral drugs for respiratory delivery and has presented preclinical data on candidates ISPM21 and ISPM19 for COVID-19, but has not yet reached clinical trials.[6]

Therapeutic areas: Infectious Diseases
Modalities: Lipid nanoparticle delivery therapyNanoparticleSmall molecule
Industry: Biotech

Drug pipeline

2 assets

ISPM19

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on InspirMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InspirMed.

Explore the full profile